{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T01:25:29Z","timestamp":1789781129211,"version":"4.0.1"},"reference-count":109,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2016,8,27]],"date-time":"2016-08-27T00:00:00Z","timestamp":1472256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Bone metastases ultimately result from a complex interaction between cancer cells and bone microenvironment. However, prior to the colonization of the bone, cancer cells must succeed through a series of steps that will allow them to detach from the primary tumor, enter into circulation, recognize and adhere to specific endothelium, and overcome dormancy. We now know that as important as the metastatic cascade, tumor cells prime the secondary organ microenvironment prior to their arrival, reflecting the existence of specific metastasis-initiating cells in the primary tumor and circulating osteotropic factors. The deep comprehension of the molecular mechanisms of bone metastases may allow the future development of specific anti-tumoral therapies, but so far the approved and effective therapies for bone metastatic disease are mostly based in bone-targeted agents, like bisphosphonates, denosumab and, for prostate cancer, radium-223. Bisphosphonates and denosumab have proven to be effective in blocking bone resorption and decreasing morbidity; furthermore, in the adjuvant setting, these agents can decrease bone relapse after breast cancer surgery in postmenopausal women. In this review, we will present and discuss some examples of applied knowledge from the bench to the bed side in the field of bone metastasis.<\/jats:p>","DOI":"10.3390\/ijms17091415","type":"journal-article","created":{"date-parts":[[2016,8,29]],"date-time":"2016-08-29T10:18:38Z","timestamp":1472465918000},"page":"1415","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6917-4477","authenticated-orcid":false,"given":"Sandra","family":"Casimiro","sequence":"first","affiliation":[{"name":"Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1567-9322","authenticated-orcid":false,"given":"Arlindo","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal"},{"name":"Oncology Division, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, 1649-028 Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Mansinho","sequence":"additional","affiliation":[{"name":"Oncology Division, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, 1649-028 Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Alho","sequence":"additional","affiliation":[{"name":"Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Costa","sequence":"additional","affiliation":[{"name":"Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal"},{"name":"Oncology Division, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, 1649-028 Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2016,8,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMra1204479","article-title":"Two hundred years of cancer research","volume":"366","author":"DeVita","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nature15756","article-title":"Tumour exosome integrins determine organotropic metastasis","volume":"527","author":"Hoshino","year":"2015","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nature03799","article-title":"Genes that mediate breast cancer metastasis to lung","volume":"436","author":"Minn","year":"2005","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/nature08021","article-title":"Genes that mediate breast cancer metastasis to the brain","volume":"459","author":"Bos","year":"2009","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrc3055","article-title":"Cancer to bone: A fatal attraction","volume":"11","author":"Weilbaecher","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrc.2016.44","article-title":"Bone metastasis: The importance of the neighbourhood","volume":"16","author":"Croucher","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumours: Recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group, Coleman, R., Powles, T., Paterson, A., Gnant, M., Anderson, S., Diel, I., Gralow, J., von Minckwitz, G., and Moebus, V. (2015). Adjuvant bisphosphonate treatment in early breast cancer: Meta-analyses of individual patient data from randomised trials. Lancet, 386, 1353\u20131361.","DOI":"10.1016\/S0140-6736(15)60908-4"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/annonc\/mdv617","article-title":"Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a european panel","volume":"27","author":"Hadji","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-med-053014-103600","article-title":"Adjuvant bisphosphonates and breast cancer survival","volume":"67","author":"Strobl","year":"2016","journal-title":"Annu. Rev. Med."},{"key":"ref_12","first-page":"98","article-title":"The distribution of secondary growths in cancer of the breast","volume":"8","author":"Paget","year":"1989","journal-title":"Cancer Metastasis Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/nm1469","article-title":"Tumor metastasis: Mechanistic insights and clinical challenges","volume":"12","author":"Steeg","year":"2006","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1546::AID-CNCR4>3.0.CO;2-I","article-title":"Mechanisms of bone metastasis","volume":"80","author":"Mundy","year":"1997","journal-title":"Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2011.59","article-title":"Rethinking the metastatic cascade as a therapeutic target","volume":"8","author":"Mina","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11914-016-0315-2","article-title":"The bone microenvironment: A fertile soil for tumor growth","volume":"14","author":"Buenrostro","year":"2016","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_17","first-page":"1","article-title":"Molecular mechanisms of bone metastasis","volume":"13","author":"Weidle","year":"2016","journal-title":"Cancer Genom. Proteom."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10585-011-9438-0","article-title":"Analysis of a bone metastasis gene expression signature in patients with bone metastasis from solid tumors","volume":"29","author":"Casimiro","year":"2012","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/cncr.24896","article-title":"Pathogenesis of osteoblastic bone metastases from prostate cancer","volume":"116","author":"Ibrahim","year":"2010","journal-title":"Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"ref_21","first-page":"345","article-title":"Receptor activator of nuclear factor-\u03baB ligand and osteoprotegerin: Maintaining the balance to prevent bone loss","volume":"5","author":"Trouvin","year":"2010","journal-title":"Clin. Interv. Aging"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1101\/gad.277681.116","article-title":"Distinctive properties of metastasis-initiating cells","volume":"30","author":"Kang","year":"2016","journal-title":"Genes Dev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"djv256","DOI":"10.1093\/jnci\/djv256","article-title":"Enhanced maf oncogene expression and breast cancer bone metastasis","volume":"107","author":"Pavlovic","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"djv360","DOI":"10.1093\/jnci\/djv360","article-title":"CAPG and GIPC1: Breast cancer biomarkers for bone metastasis development and treatment","volume":"108","author":"Westbrook","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ccr.2011.11.002","article-title":"VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging \u03b14\u03b21-positive osteoclast progenitors","volume":"20","author":"Lu","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.canlet.2015.11.009","article-title":"The influence of the pre-metastatic niche on breast cancer metastasis","volume":"380","author":"Siegel","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ctrv.2016.02.002","article-title":"Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer","volume":"44","author":"Vignani","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/bonekey.2015.56","article-title":"Tumour-derived mirnas and bone metastasis","volume":"4","author":"Croset","year":"2015","journal-title":"Bonekey Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"10954","DOI":"10.1073\/pnas.1830978100","article-title":"A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases","volume":"100","author":"Yin","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6213s","DOI":"10.1158\/1078-0432.CCR-06-1007","article-title":"Basic mechanisms responsible for osteolytic and osteoblastic bone metastases","volume":"12","author":"Guise","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10555-013-9420-1","article-title":"The pre-metastatic niche: Finding common ground","volume":"32","author":"Sceneay","year":"2013","journal-title":"Cancer Metastasis Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/bonekey.2012.80","article-title":"The pre-metastatic niche: Is metastasis random?","volume":"1","author":"Cox","year":"2012","journal-title":"Bonekey Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/aja.2011.164","article-title":"The prostate cancer bone marrow niche: More than just \u201cfertile soil\u201d","volume":"14","author":"Pedersen","year":"2012","journal-title":"Asian J. Androl."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"9621","DOI":"10.1158\/0008-5472.CAN-10-1722","article-title":"Cancer exosomes trigger fibroblast to myofibroblast differentiation","volume":"70","author":"Webber","year":"2010","journal-title":"Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s10735-012-9415-1","article-title":"Microvesicles released from hormone-refractory prostate cancer cells facilitate mouse pre-osteoblast differentiation","volume":"43","author":"Itoh","year":"2012","journal-title":"J. Mol. Histol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.semcancer.2012.03.007","article-title":"New insights into the mechanisms of organ-specific breast cancer metastasis","volume":"22","author":"Lorusso","year":"2012","journal-title":"Semin. Cancer Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10555-006-9019-x","article-title":"The pivotal role of CXCL12 (SDF-1)\/CXCR4 axis in bone metastasis","volume":"25","author":"Wang","year":"2006","journal-title":"Cancer Metastasis Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/35065016","article-title":"Involvement of chemokine receptors in breast cancer metastasis","volume":"410","author":"Muller","year":"2001","journal-title":"Nature"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1535-6108(03)00132-6","article-title":"A multigenic program mediating breast cancer metastasis to bone","volume":"3","author":"Kang","year":"2003","journal-title":"Cancer Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1158\/0008-5472.967.65.3","article-title":"Silencing of CXCR4 blocks breast cancer metastasis","volume":"65","author":"Liang","year":"2005","journal-title":"Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/jcb.10522","article-title":"Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo","volume":"89","author":"Sun","year":"2003","journal-title":"J. Cell. Biochem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1359\/JBMR.041109","article-title":"Skeletal localization and neutralization of the SDF-1(CXCL12)\/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo","volume":"20","author":"Sun","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/pros.20500","article-title":"Expression and activation of \u03b1v\u03b23 integrins by SDF-1\/CXC12 increases the aggressiveness of prostate cancer cells","volume":"67","author":"Sun","year":"2007","journal-title":"Prostate"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/pros.20318","article-title":"CXCL12\/CXCR4 signaling activates AKT-1 and MMP-9 expression in prostate cancer cells: The role of bone microenvironment-associated CXCL12","volume":"66","author":"Chinni","year":"2006","journal-title":"Prostate"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.cellsig.2005.03.022","article-title":"Diverse signaling pathways through the SDF-1\/CXCR4 chemokine axis in prostate cancer cell lines leads to altered patterns of cytokine secretion and angiogenesis","volume":"17","author":"Wang","year":"2005","journal-title":"Cell Signal."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1172\/JCI43414","article-title":"Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow","volume":"121","author":"Shiozawa","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1158\/1541-7786.MCR-11-0404","article-title":"Disseminated prostate cancer cells can instruct hematopoietic stem and progenitor cells to regulate bone phenotype","volume":"10","author":"Joseph","year":"2012","journal-title":"Mol. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Taichman, R.S., Patel, L.R., Bedenis, R., Wang, J., Weidner, S., Schumann, T., Yumoto, K., Berry, J.E., Shiozawa, Y., and Pienta, K.J. (2013). Gas6 receptor status is associated with dormancy and bone metastatic tumor formation. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0061873"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ccell.2014.11.017","article-title":"The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells","volume":"27","author":"Wang","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/415530a","article-title":"Gene expression profiling predicts clinical outcome of breast cancer","volume":"415","author":"Dai","year":"2002","journal-title":"Nature"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10549-008-0191-2","article-title":"Validation of 70-gene prognosis signature in node-negative breast cancer","volume":"117","author":"Linn","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/jnci\/djj329","article-title":"Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer","volume":"98","author":"Buyse","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1056\/NEJMoa021967","article-title":"A gene-expression signature as a predictor of survival in breast cancer","volume":"347","author":"He","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s10549-010-0814-2","article-title":"The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer","volume":"120","author":"Knauer","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1245\/s10434-009-0902-x","article-title":"Metastatic potential of T1 breast cancer can be predicted by the 70-gene mammaprint signature","volume":"17","author":"Mook","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/annonc\/mdp388","article-title":"The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age","volume":"21","author":"Mook","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s10549-013-2831-4","article-title":"Long-term impact of the 70-gene signature on breast cancer outcome","volume":"143","author":"Drukker","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","article-title":"Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer","volume":"24","author":"Paik","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1200\/JCO.2007.14.4501","article-title":"Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features","volume":"26","author":"Goldstein","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1200\/JCO.2008.20.2119","article-title":"Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection","volume":"28","author":"Lo","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1470-2045(09)70314-6","article-title":"Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial","volume":"11","author":"Albain","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"6740","DOI":"10.1073\/pnas.0701138104","article-title":"Lung metastasis genes couple breast tumor size and metastatic spread","volume":"104","author":"Minn","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1172\/JCI22320","article-title":"Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors","volume":"115","author":"Minn","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1200\/JCO.2005.03.8802","article-title":"Genes associated with breast cancer metastatic to bone","volume":"24","author":"Smid","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10549-016-3741-z","article-title":"A novel gene expression signature for bone metastasis in breast carcinomas","volume":"156","author":"Halfwerk","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10585-014-9642-9","article-title":"Genetics of breast cancer bone metastasis: A sequential multistep pattern","volume":"31","author":"Fazilaty","year":"2014","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"6222s","DOI":"10.1158\/1078-0432.CCR-06-0843","article-title":"Molecular mechanisms of action of bisphosphonates: Current status","volume":"12","author":"Roelofs","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.3816\/CBC.2009.s.002","article-title":"Maintaining bone density in patients undergoing treatment for breast cancer: Is there an adjuvant benefit?","volume":"9","author":"Gnant","year":"2009","journal-title":"Clin. Breast Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab vs. zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab vs. zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid vs. placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial\u2014The zoledronic acid lung cancer and other solid tumors study group","volume":"21","author":"Rosen","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Wong, M.H., Stockler, M.R., and Pavlakis, N. (2012). Bisphosphonates and other bone agents for breast cancer. Cochrane Library, CD003474.","DOI":"10.1002\/14651858.CD003474.pub3"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S1470-2045(13)70539-4","article-title":"Oral ibandronic acid vs. intravenous zoledronic acid in treatment of bone metastases from breast cancer: A randomised, open label, non-inferiority phase 3 trial","volume":"15","author":"Casbard","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_81","first-page":"S53","article-title":"Treatment of skeletal disease in breast cancer: A controlled clodronate trial","volume":"8","author":"Elomaa","year":"1987","journal-title":"Bone"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","article-title":"Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer","volume":"11","author":"Paterson","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.1993.11.3.491","article-title":"Palliative pamidronate treatment in patients with bone metastases from breast cancer","volume":"11","author":"Kroon","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","article-title":"Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial","volume":"17","author":"Theriault","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_86","first-page":"377","article-title":"Zoledronic acid vs. pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF02549644","article-title":"Effect of oral clodronate on bone pain","volume":"24","author":"Elomaa","year":"1992","journal-title":"Int. Urol. Nephrol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/bjc.1997.488","article-title":"Concomitant IV and oral clodronate in the relief of bone pain\u2014A double-blind placebo-controlled study in patients with prostate cancer","volume":"76","author":"Kylmala","year":"1997","journal-title":"Br. J. Cancer"},{"key":"ref_89","first-page":"177a","article-title":"Randomized, placebo-controlled trial of mitoxantrone\/prednisone and clodronate vs. mitoxantrone\/prednisone alone in patients with hormone-refractory prostate cancer (HRPC) and pain","volume":"21","author":"Ernst","year":"2002","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1081\/CNV-120014886","article-title":"The new bisphosphonate, zometa decreases skeletal complications in both lytic and blastic lesions: A comparision to pamidronate","volume":"20","author":"Lipton","year":"2002","journal-title":"Cancer Investig."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","article-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (alliance)","volume":"32","author":"Smith","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1470-2045(13)70583-7","article-title":"Which bisphosphonate to treat bone metastases?","volume":"15","author":"Costa","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/jcb.22403","article-title":"Pathogenesis of myeloma bone disease","volume":"109","author":"Roodman","year":"2010","journal-title":"J. Cell. Biochem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma aredia study group","volume":"16","author":"Berenson","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2009.0076","article-title":"NCCN task force report: Bone health in cancer care","volume":"7","author":"Gralow","year":"2009","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","article-title":"Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: Results from a phase 3, double-blind, randomised trial","volume":"15","author":"Sartor","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.eururo.2015.09.005","article-title":"Radiopharmaceuticals for palliation of bone pain in patients with castration-resistant prostate cancer metastatic to bone: A systematic review","volume":"70","author":"Jong","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.eururo.2016.03.056","article-title":"Radiopharmaceuticals: A path forward","volume":"70","author":"Sartor","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/bonekey.2013.1","article-title":"Mechanisms of action of bisphosphonates in oncology: A scientific concept evolving from antiresorptive to anticancer activities","volume":"2","author":"Clezardin","year":"2013","journal-title":"Bonekey Rep."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/annonc\/mdu544","article-title":"Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen vs. anastrozol plus ovarian function suppression in premenopausal early breast cancer: Final analysis of the austrian breast and colorectal cancer study group trial 12","volume":"26","author":"Gnant","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1200\/jco.2015.33.15_suppl.503","article-title":"Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG\/Alliance\/ECOG-ACRIN\/NCIC clinical trials group\/NRG oncology study S0307","volume":"33","author":"Gralow","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): A multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"S2-02","DOI":"10.1158\/1538-7445.SABCS15-S2-02","article-title":"The impact of adjuvant denosumab on disease-free survival: Results from 3425 postmenopausal patients of the ABCSG-18 trial","volume":"76","author":"Gnant","year":"2016","journal-title":"Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.eururo.2014.02.014","article-title":"Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: Efficacy and safety results of the zometa european study (ZEUS)","volume":"67","author":"Wirth","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S1470-2045(14)70328-6","article-title":"Short-term androgen suppression and radiotherapy vs. intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): An open-label, randomised, phase 3 factorial trial","volume":"15","author":"Denham","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1517\/13543784.2016.1142972","article-title":"Targeted agents in preclinical and early clinical development for the treatment of cancer bone metastases","volume":"25","author":"Hiraga","year":"2016","journal-title":"Expert Opin. Investig. Drugs"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/17\/9\/1415\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:29:24Z","timestamp":1760210964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/17\/9\/1415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,27]]},"references-count":109,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2016,9]]}},"alternative-id":["ijms17091415"],"URL":"https:\/\/doi.org\/10.3390\/ijms17091415","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,27]]}}}